Integris Medtech gets SEBI’s approval to float IPO
The IPO comprises a fresh issue of equity shares worth Rs 925 crore and an offer for sale of 2.16 crore equity shares by promoters
Integris Medtech has secured Securities and Exchange Board of India’s (SEBI's) approval to raise funds through initial public offering (IPO). The IPO comprises a fresh issue of equity shares worth Rs 925 crore and an offer for sale of 2.16 crore equity shares by promoters.
Proceeds of the fresh issue will primarily be used for payment of debt and general corporate purposes. ICICI Securities, Axis Capital, Citigroup Global Markets India and IIFL Capital Services are the book-running lead managers for the IPO. The shares of the company are proposed to be listed on theBSE and the NSE.
Co-founded by Gurmit Singh Chugh and Punita Sharma, the firm has expertise in developing, manufacturing, commercialising and selling a broad and integrated portfolio of medical devices and solutions. Its portfolio includes cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
